Dr. Xin Wang 王欣
Chief Physician, Associate Professor
Department of Breast Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis, functional surgery, and individualized treatment for breast cancer. Procedures include radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, minimally invasive surgery, and ductoscopy.
Dr. Wang holds a medical doctorate from Lund University, Sweden (2001) and a bachelor’s degree from Tianjin Medical University (1991). As Deputy Chief Physician and Associate Professor, Dr. Wang focuses on breast cancer care and clinical trials. Research includes CysLT receptors and the Rb tumor suppressor. Dr. Wang has published over 40 papers, including 29 SCI-indexed articles.
Professional roles
- Youth Member, Breast Cancer Professional Committee, China Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Cancer Prevention and Treatment
- Editorial Board Member, Chinese Journal of Clinical Oncology (English Edition)
Name order: in Chinese the family name comes first (Wang Xin). Papers usually list the name as Xin Wang or Wang X.
Selected publications
209 papers on PubMed matched by name and affiliation; 48 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin J Cancer Res, 2026 (senior author): A programmed cell death learning signature predicts immunotherapy response and identifies AP1S1 as a regulator of immune exclusion in breast cancer. PubMed 42712842
- Front Pharmacol, 2026 (senior author): Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin's role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis. PubMed 42719185
- Cell Death Dis, 2026 (senior author): MND1 reduces breast cancer chemosensitivity by promoting RAD51-mediated homologous recombination repair. PubMed 42236675
- Front Immunol, 2026 (senior author): Integrative multi-omics and radiomics reveal a TMSB10-driven cell state for non-invasive assessment and precision stratification in breast cancer. PubMed 42088484
- Int J Biol Macromol, 2026 (senior author): Subtype-specific APOBEC enrichment links genomic instability to predict immunotherapy response in breast cancer subtypes. PubMed 41865932
- Breast Cancer Res, 2026 (senior author): Deubiquitination and stabilization of EIF4A3 by OTUB2 contributes to TPI1-mediated glycolysis and TNBC progression. PubMed 41857621
- Endocrine, 2026 (senior author): Symptom clusters and contemporaneous symptom network analysis at discharge in patients with differentiated thyroid cancer after thyroidectomy. PubMed 41803333
- Gastroenterol Rep (Oxf), 2025 (senior author): High expression of IQGAP3 promotes the infiltration of M0 macrophages into the TME, resulting in a poor prognosis for gastric cancer patients. PubMed 41446602
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion